Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Akebia Therapeutics (DE:AX9)
BERLIN:AX9
RESEARCH TOOLSreports
Akebia Therapeutics (AX9) Stock Price & Analysis
2 Followers
AX9 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.74 - €2.85
Previous Close€1.19
Volume0.00
Average Volume (3M)2.69K
Market Cap
€262.14M
Enterprise Value€262.80M
Total Cash (Recent Filing)$42.92M
Total Debt (Recent Filing)$43.63M
Price to Earnings (P/E)N/A
Beta0.66
Next Earnings
May 06, 2024EPS Estimate
-€0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding209,372,275
10 Day Avg. Volume0
30 Day Avg. Volume2,689
Standard Deviation0.16
R-Squared0.46
Alpha0.00648
Financial Highlights & Ratios
Price to Book (P/B)-2.23
Price to Sales (P/S)2.45
Price to Cash Flow (P/CF)-30.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.46
Enterprise Value/Gross Profit2.18
Enterprise Value/Ebitda-36.56
Forecast
1Y Price Target
€4.67Price Target Upside291.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Akebia Therapeutics News
PremiumCompany Announcements
Akebia Therapeutics Celebrates FDA Approval of Anemia Drug
PremiumCompany Announcements
Akebia Therapeutics Announces CFO Transition and Interim PlanBulls Say, Bears Say
Bulls Say
Competitive AdvantageThe Vafseo label includes a simple dosing regimen and does not carry a warning for 'risk of hospitalization for heart failure' unlike its competitor, providing a potential advantage.
Financial HealthCompany has sufficient cash runway to fund operations for 24 months, ensuring stability while awaiting vadadustat's approval.
Regulatory ApprovalFDA approves Vafseo for anemia in CKD on dialysis, marking a significant regulatory milestone.
Bears Say
Drug Safety PerceptionVafseo's label comes with black box warnings, which are standard for drugs in its class but may affect its perception among prescribers and patients.
Financial StabilityAkebia must maintain a cash balance of at least $15M or achieve total revenue over $150M to meet the key financial covenant of the loan.
Regulatory ApprovalRisks include potential failure to secure FDA approval for vadadustat in dialysis.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.56% Other Institutional Investors
99.44% Public Companies and
Individual Investors
AX9 FAQ
What was Akebia Therapeutics’s price range in the past 12 months?
Akebia Therapeutics lowest stock price was €0.74 and its highest was €2.85 in the past 12 months.
What is Akebia Therapeutics’s market cap?
Currently, no data Available
When is Akebia Therapeutics’s upcoming earnings report date?
Akebia Therapeutics’s upcoming earnings report date is May 06, 2024 which is in 7 days.
How were Akebia Therapeutics’s earnings last quarter?
Akebia Therapeutics released its earnings results on Mar 14, 2024. The company reported €0 earnings per share for the quarter, beating the consensus estimate of -€0.035 by €0.035.
Is Akebia Therapeutics overvalued?
According to Wall Street analysts Akebia Therapeutics’s price is currently Undervalued.
Does Akebia Therapeutics pay dividends?
Akebia Therapeutics does not currently pay dividends.
What is Akebia Therapeutics’s EPS estimate?
Akebia Therapeutics’s EPS estimate is -€0.07.
How many shares outstanding does Akebia Therapeutics have?
Currently, no data Available
What happened to Akebia Therapeutics’s price movement after its last earnings report?
Akebia Therapeutics reported an EPS of €0 in its last earnings report, beating expectations of -€0.035. Following the earnings report the stock price went up 12.558%.
Which hedge fund is a major shareholder of Akebia Therapeutics?
Among the largest hedge funds holding Akebia Therapeutics’s share is Graham Capital Management, L.P.. It holds Akebia Therapeutics’s shares valued at 29K.
---
Akebia Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€4.67 (291.27% Upside)
€4.67 (291.27% Upside)
Blogger Sentiment
Bullish
DE:AX9 Sentiment 75%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $300.7K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
68.97%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-32.12%
Trailing 12-Months
Company Description
Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
---
AX9 Earnings Call
Q3 2023
0:00 / 0:00
---
AX9 Stock 12 Months Forecast
Average Price Target
€4.67
▲(291.27% Upside)
Technical Analysis
Akebia Therapeutics
―
Arrowhead Pharmaceuticals
―
Xencor
―
Corbus Pharmaceuticals
―
Karyopharm Therapeutics
―
Best Analysts Covering AX9
1 Year
1 Year Success Rate
4/16 ratings generated profit
1 Year Average Return
-24.15%
reiterated a buy rating 28 days ago
Copying Ed Arce's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -24.15% per trade.
---